AI summary & key facts
Louis warns that experimental PCSK9 gene therapies for lowering LDL may be unsafe because people have died in trials, and notes that safe, effective drugs already exist, including PCSK9 inhibitors. He clarifies that the deaths were specific to the gene therapy in that trial, with unclear cause, and were not seen in long PCSK9 inhibitor drug trials.
- A patient died after experimental gene editing to lower cholesterol (Verve trial)
- Louis: no reason to take gene therapy risk until FDA-approved and proven safe
- Nothing similar was seen in large long-running PCSK9 inhibitor trials
PCSK9 gene therapies to lower LDL may not be safe.
People have died in the trials.
We have safe drugs that lower LDL very effectively, including drugs that safely inhibit PCSK9.
For most people, there is no good reason to take the risk of gene therapy to lower LDL until it is approved by the FDA and proven safe.
Please note:
These deaths were very specific to the gene therapy in this particular trial. The cause is unclear.
Nothing like this was seen in large long-running drug trials for PCSK9 inhibitors.
#genetherapyHD #pcsk9HD #verve102HD #verve101HD